IL243522B - 6-n-bis(aryl or heteroaryl)-5,3,1-triazine-4,2-diamine compounds as idh2 mutant inhibitors for cancer treatment - Google Patents
6-n-bis(aryl or heteroaryl)-5,3,1-triazine-4,2-diamine compounds as idh2 mutant inhibitors for cancer treatmentInfo
- Publication number
- IL243522B IL243522B IL243522A IL24352216A IL243522B IL 243522 B IL243522 B IL 243522B IL 243522 A IL243522 A IL 243522A IL 24352216 A IL24352216 A IL 24352216A IL 243522 B IL243522 B IL 243522B
- Authority
- IL
- Israel
- Prior art keywords
- triazine
- heteroaryl
- cancer
- aryl
- bis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845352P | 2013-07-11 | 2013-07-11 | |
| PCT/US2014/046204 WO2015006592A1 (en) | 2013-07-11 | 2014-07-10 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL243522A0 IL243522A0 (en) | 2016-02-29 |
| IL243522B true IL243522B (en) | 2021-06-30 |
Family
ID=51261261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243522A IL243522B (en) | 2013-07-11 | 2016-01-07 | 6-n-bis(aryl or heteroaryl)-5,3,1-triazine-4,2-diamine compounds as idh2 mutant inhibitors for cancer treatment |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9724350B2 (enExample) |
| EP (1) | EP3019490B1 (enExample) |
| JP (1) | JP6471155B2 (enExample) |
| KR (1) | KR102302091B1 (enExample) |
| CN (1) | CN105492435B (enExample) |
| AU (1) | AU2014287122B9 (enExample) |
| BR (1) | BR112016000489A8 (enExample) |
| CA (1) | CA2917592A1 (enExample) |
| CL (1) | CL2016000045A1 (enExample) |
| CR (1) | CR20160022A (enExample) |
| EA (1) | EA032070B1 (enExample) |
| ES (1) | ES2807582T3 (enExample) |
| IL (1) | IL243522B (enExample) |
| MX (1) | MX375030B (enExample) |
| MY (1) | MY185687A (enExample) |
| NI (1) | NI201600007A (enExample) |
| NZ (1) | NZ715738A (enExample) |
| PE (1) | PE20160744A1 (enExample) |
| PH (1) | PH12016500055B1 (enExample) |
| SA (1) | SA516370386B1 (enExample) |
| SG (1) | SG11201600058XA (enExample) |
| UA (1) | UA119242C2 (enExample) |
| WO (1) | WO2015006592A1 (enExample) |
| ZA (1) | ZA201600210B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2807582T3 (es) * | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer |
| US10376510B2 (en) | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015017821A2 (en) | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| MX381582B (es) * | 2015-10-15 | 2025-03-12 | Celgene Corp | Terapia de combinacion para el tratamiento de neoplasias malignas. |
| CA3001599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| WO2017146795A1 (en) | 2016-02-26 | 2017-08-31 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours |
| CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| EP3489230B1 (en) * | 2016-07-21 | 2021-12-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| PL3644999T3 (pl) | 2017-06-30 | 2023-05-08 | Celgene Corporation | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu |
| CN109467538A (zh) * | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| CN110054617A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类化合物、其制备方法及用途 |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| CN111662242B (zh) * | 2019-03-08 | 2023-10-24 | 中国药科大学 | 杂环类idh突变体抑制剂、其制备方法及用途 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| CN112250639B (zh) * | 2020-11-19 | 2022-05-24 | 浙江工业大学 | 一种杂环取代的芳胺类化合物及其制备方法和应用 |
| CN112592958B (zh) * | 2020-12-07 | 2022-11-01 | 山东大学第二医院 | 利用fad依赖型d-2-羟基戊二酸脱氢酶和刃天青检测d-2-羟基戊二酸的方法 |
| CN112645893A (zh) * | 2020-12-28 | 2021-04-13 | 营口昌成新材料科技有限公司 | 一种二卤代均三嗪的合成方法 |
| CN115536637B (zh) * | 2022-10-24 | 2025-03-18 | 陕西中医药大学 | 一种均三嗪类衍生物及其合成方法与用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) * | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
| JPS5011392B2 (enExample) * | 1971-08-07 | 1975-04-30 | ||
| CH606334A5 (enExample) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
| JPS58186682A (ja) * | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| DE69322076D1 (de) | 1992-02-28 | 1998-12-17 | Zenyaku Kogyo Kk | S-triazin-derivate und diese als aktiven wirkstoff enthaltende heilmittel gegen östrogen abhängige krankheiten |
| WO1998021191A1 (en) | 1995-05-16 | 1998-05-22 | Nissan Chemical Industries, Ltd. | Cyanoethylmelamine derivatives and process for producing the same |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
| EP1187825A1 (en) * | 1999-06-07 | 2002-03-20 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| US7038046B2 (en) | 2001-08-17 | 2006-05-02 | Ciba Specialty Chemicals Corporation | Triazine derivatives and their use as sunscreens |
| JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
| WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
| HUE029020T2 (en) * | 2002-07-18 | 2017-02-28 | Janssen Pharmaceutica Nv | Substituted triazine kinase inhibitors |
| JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | ＴＮＦ−α産生抑制剤 |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| AU2003293333A1 (en) | 2002-12-02 | 2004-06-23 | Arqule, Inc. | Method of treating cancers |
| AU2003299641C1 (en) | 2002-12-16 | 2016-06-02 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
| EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| AU2003297904A1 (en) | 2003-12-12 | 2005-07-14 | University Of Maryland, Baltimore | Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain |
| BRPI0417213A (pt) | 2003-12-24 | 2007-02-06 | Scios Inc | tratamento de gliomas malìgnos com inibidores de tgf-beta |
| CA2581623A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyridine compounds, process for their preparation and compositions containing them |
| AU2006208834A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| CN101679371A (zh) | 2006-12-04 | 2010-03-24 | 艾美罗股份公司 | 作为腺苷受体拮抗剂的取代的嘧啶 |
| EP2923703B1 (en) | 2006-12-15 | 2018-09-19 | NantBio, Inc. | Triazine derivatives and their therapeutical applications |
| EP2152676B1 (en) | 2007-04-30 | 2013-04-03 | ProMetic BioSciences Inc. | "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives" |
| AU2008262291A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| EA201070451A1 (ru) | 2007-10-10 | 2010-10-29 | Такеда Фармасьютикал Компани Лимитед | Амидные соединения |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
| CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
| WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
| JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| HRP20140265T1 (hr) | 2009-02-06 | 2014-04-25 | Nippon Shinyaku Co., Ltd. | Derivat aminopirazina i odgovarajuä†i lijek |
| ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| US20120238576A1 (en) | 2009-06-08 | 2012-09-20 | California Capital Equity, Llc | Triazine Derivatives and their Therapeutical Applications |
| AU2010258974A1 (en) | 2009-06-09 | 2012-01-12 | California Capital Equity, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
| CN102573481A (zh) * | 2009-06-09 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 脲基苯基取代的三嗪衍生物及其治疗应用 |
| WO2011005208A1 (en) | 2009-07-10 | 2011-01-13 | Milux Holding S.A. | Knee joint device and method |
| JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| EP2525790B1 (en) | 2009-10-21 | 2020-05-27 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| EP2509600B1 (en) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| EP2553116A4 (en) | 2010-04-01 | 2013-10-23 | Agios Pharmaceuticals Inc | METHOD FOR IDENTIFYING A CANDIDATE COMPOUND |
| ES2704862T3 (es) | 2010-07-16 | 2019-03-20 | Agios Pharmaceuticals Inc | Composiciones terapéuticamente activas y su método de uso |
| EP2646423A4 (en) | 2010-11-29 | 2014-04-30 | Galleon Pharmaceuticals Inc | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR THE TREATMENT OF RESPIRATORY DISORDERS OR DISEASES |
| EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
| LT2800743T (lt) | 2012-01-06 | 2018-06-25 | Agios Pharmaceuticals, Inc. | Terapiškai aktyvūs junginiai ir jų panaudojimo būdai |
| JP6228130B2 (ja) | 2012-01-19 | 2017-11-08 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療活性化合物およびそれらの使用方法 |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| CN104169260A (zh) * | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | 新三嗪衍生物 |
| ES2807582T3 (es) * | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2014
- 2014-07-10 ES ES14745309T patent/ES2807582T3/es active Active
- 2014-07-10 JP JP2016525491A patent/JP6471155B2/ja active Active
- 2014-07-10 PE PE2016000042A patent/PE20160744A1/es unknown
- 2014-07-10 CA CA2917592A patent/CA2917592A1/en not_active Abandoned
- 2014-07-10 KR KR1020167003352A patent/KR102302091B1/ko active Active
- 2014-07-10 MX MX2016000336A patent/MX375030B/es active IP Right Grant
- 2014-07-10 BR BR112016000489A patent/BR112016000489A8/pt not_active Application Discontinuation
- 2014-07-10 EA EA201690204A patent/EA032070B1/ru not_active IP Right Cessation
- 2014-07-10 SG SG11201600058XA patent/SG11201600058XA/en unknown
- 2014-07-10 US US14/904,032 patent/US9724350B2/en active Active
- 2014-07-10 AU AU2014287122A patent/AU2014287122B9/en active Active
- 2014-07-10 CN CN201480047026.XA patent/CN105492435B/zh active Active
- 2014-07-10 WO PCT/US2014/046204 patent/WO2015006592A1/en not_active Ceased
- 2014-07-10 MY MYPI2016700044A patent/MY185687A/en unknown
- 2014-07-10 EP EP14745309.6A patent/EP3019490B1/en active Active
- 2014-07-10 NZ NZ715738A patent/NZ715738A/en unknown
- 2014-10-07 UA UAA201601118A patent/UA119242C2/uk unknown
-
2016
- 2016-01-07 PH PH12016500055A patent/PH12016500055B1/en unknown
- 2016-01-07 IL IL243522A patent/IL243522B/en active IP Right Grant
- 2016-01-08 NI NI201600007A patent/NI201600007A/es unknown
- 2016-01-11 CR CR20160022A patent/CR20160022A/es unknown
- 2016-01-11 ZA ZA2016/00210A patent/ZA201600210B/en unknown
- 2016-01-11 SA SA516370386A patent/SA516370386B1/ar unknown
- 2016-01-11 CL CL2016000045A patent/CL2016000045A1/es unknown
-
2017
- 2017-06-22 US US15/630,886 patent/US10111878B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201600210B (en) | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer | |
| IL289793A (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201607706SA (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| HRP20221051T1 (hr) | Heterociklički spojevi kao inhibitori ret kinaze | |
| EA201491456A1 (ru) | Соединения-ингибиторы raf | |
| SI3505173T1 (sl) | Pirolo(1,2-F)(1,2,4)triazini, uporabni za zdravljenje okužb z respiratornim sincicijskim virusom | |
| IL250875A0 (en) | History of aminotriazines useful as tank-binding kinase inhibitory compounds | |
| PL2922828T3 (pl) | Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka | |
| IL247319B (en) | History of 2-hydroxy-6,4-diphenyl-[5,3,1]triazine as mpges-1 inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| MX2016009663A (es) | Derivados de icariina. | |
| EP4169918B8 (en) | Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer | |
| IL242546A0 (en) | New compounds for cancer treatment | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| SG11201809760TA (en) | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | |
| PT3296294T (pt) | Composto para tratamento ou prevenção do cancro de mama | |
| SI3423440T1 (sl) | 5-metil-6-fenil-4,5-dihidro-2H-piridazin-3-ON derivat za zdravljenje možganskih tumorjev | |
| SG11201605182PA (en) | CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND | |
| TH1601000068A (th) | สารประกอบ n,6-บิส(เอริล หรือเฮเทอโรเอริล)-1,3,5-ไตรอะซีน-2,4-ไดเอมีน ดังที่เป็นตัวยับยั้งการ กลายพันธุ์ idh2 สำหรับการรักษามะเร็ง | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |